{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:42:59Z","timestamp":1791186179481,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":351,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RE\/18\/6\/34217"],"award-info":[{"award-number":["RE\/18\/6\/34217"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Patients with a reduced left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) are considered to be at risk of progressive adverse cardiac remodelling which can lead to the development of heart failure and death. The early addition of a sodium\u2013glucose cotransporter 2 (SGLT2) inhibitor to standard treatment may delay or prevent progressive adverse remodelling in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We performed a randomized, double-blind, placebo-controlled, multicentre trial using cardiovascular magnetic resonance imaging (MRI), in patients with left ventricular systolic dysfunction following MI. Eligible patients were those \u226512\u2009h and \u226414\u2009days following acute MI, with an LVEF &amp;lt;45% by MRI. Patients were randomized to empagliflozin 10\u2009mg once a day or matching placebo. The primary outcome was the change in left ventricular end-systolic volume indexed to body surface area (LVESVI) from baseline to 24\u2009weeks. Secondary outcomes included measures of left ventricular and atrial volumes, left ventricular mass, LVEF, and high-sensitivity troponin I (hs-TnI) and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) concentrations. From October 2022 to January 2024, 105 eligible patients were randomized. The mean age was 63\u2009\u00b1\u200911\u2009years and 90 (87%) were male. The mean LVEF was 34.8\u2009\u00b1\u20096.0%. In the placebo group, LVESVI decreased by 7.8\u2009\u00b1\u200916.3\u2009ml\/m2, left ventricular end-diastolic volume index (LVEDVI) did not change (\u22120.3\u2009\u00b1\u200918.7\u2009ml\/m2) and LVEF increased by 8.5\u2009\u00b1\u20097.4% at 24\u2009weeks from baseline. Empagliflozin did not affect the change in LVESVI from baseline to 24\u2009weeks (between-group difference\u2009=\u20090.3\u2009ml\/m2, 95% confidence interval \u22125.2 to 5.8; p\u2009=\u20090.92). Compared with placebo, empagliflozin also had no effect on LVEDVI, LVEF, left atrial volume index, left ventricular mass index, NT-proBNP, or hs-TnI, but did increase haematocrit and reduced uric acid and weight.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with left ventricular systolic dysfunction after an acute MI receiving contemporary standard of care, treatment with empagliflozin had no effect on cardiac volumes or LVEF compared with placebo. Progressive adverse cardiac remodelling did not occur in the majority of patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3560","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T20:19:36Z","timestamp":1734293976000},"page":"566-576","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Empagliflozin to Prevent Worsening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction (EMPRESS-MI)"],"prefix":"10.1093","volume":"27","author":[{"given":"Jaclyn","family":"Carberry","sequence":"first","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Stanley","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriona J.M.","family":"Brooksbank","sequence":"additional","affiliation":[{"name":"West of Scotland Innovation Hub, National Health Service Scotland , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Good","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kellman","sequence":"additional","affiliation":[{"name":"National Heart, Lung, and Blood Institute, National Institutes of Health , Bethesda, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian N.","family":"Lang","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mitchell","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Mangion","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S.","family":"Gardner","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Mark","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Meyer","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Orchard","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aadil","family":"Shaukat","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Watkins","sequence":"additional","affiliation":[{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"McConnachie","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Welsh","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Berry","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]},{"name":"Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"key":"2026010913023060700_ejhf3560-bib-0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002460","article-title":"Mortality associated with heart failure after myocardial infarction: A contemporary community perspective","volume":"9","author":"Gerber","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026010913023060700_ejhf3560-bib-0002","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/ejhf.2965","article-title":"Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991\u20132016","volume":"25","author":"Docherty","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913023060700_ejhf3560-bib-0003","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jchf.2014.10.007","article-title":"Incidence, temporal trends, and prognostic impact of heart failure complicating acute myocardial infarction. The SWEDEHEART registry (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies): A study of 199,851 patients admitted with index acute myocardial infarctions, 1996 to 2008","volume":"3","author":"Desta","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026010913023060700_ejhf3560-bib-0004","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1161\/01.CIR.89.1.68","article-title":"Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril","volume":"89","author":"Sutton","year":"1994","journal-title":"Circulation"},{"key":"2026010913023060700_ejhf3560-bib-0005","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM198603273141303","article-title":"A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction","volume":"314","author":"O'Neill","year":"1986","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0006","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0007","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJM198807143190204","article-title":"Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction","volume":"319","author":"Pfeffer","year":"1988","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0008","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1161\/CIRCULATIONAHA.104.508093","article-title":"Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction","volume":"111","author":"Solomon","year":"2005","journal-title":"Circulation"},{"key":"2026010913023060700_ejhf3560-bib-0009","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN Echo Substudy","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"2026010913023060700_ejhf3560-bib-0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0011","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"key":"2026010913023060700_ejhf3560-bib-0012","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0013","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"2026010913023060700_ejhf3560-bib-0014","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0015","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0016","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.ahj.2009.04.001","article-title":"Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?","volume":"157","author":"Weir","year":"2009","journal-title":"Am Heart J"},{"key":"2026010913023060700_ejhf3560-bib-0017","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0018","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.122.059210","article-title":"Impact of sacubitril\/valsartan compared with ramipril on cardiac structure and function after acute myocardial infarction: The PARADISE-MI Echocardiographic Substudy","volume":"146","author":"Shah","year":"2022","journal-title":"Circulation"},{"key":"2026010913023060700_ejhf3560-bib-0019","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2026010913023060700_ejhf3560-bib-0020","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"2026010913023060700_ejhf3560-bib-0021","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: A substudy of the Empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0023","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0024","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: Insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"2026010913023060700_ejhf3560-bib-0025","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2023","journal-title":"NEJM Evid"},{"key":"2026010913023060700_ejhf3560-bib-0026","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/ehf2.14830","article-title":"Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): Rationale and design","volume":"11","author":"Carberry","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026010913023060700_ejhf3560-bib-0027","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2018.08.1038","article-title":"Fourth universal definition of myocardial infarction (2018)","volume":"72","author":"Thygesen","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0028","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.119.009937","article-title":"Redefining adverse and reverse left ventricular remodeling by cardiovascular magnetic resonance following ST-segment-elevation myocardial infarction and their implications on long-term prognosis","volume":"13","author":"Bulluck","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026010913023060700_ejhf3560-bib-0029","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1161\/CIRCULATIONAHA.115.019949","article-title":"Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: The OMEGA-REMODEL randomized clinical trial","volume":"134","author":"Heydari","year":"2016","journal-title":"Circulation"},{"key":"2026010913023060700_ejhf3560-bib-0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7326\/0003-4819-134-6-200103200-00009","article-title":"Recovery of ventricular function after myocardial infarction in the reperfusion era: The Healing and Early Afterload Reducing Therapy study","volume":"134","author":"Solomon","year":"2001","journal-title":"Ann Intern Med"},{"key":"2026010913023060700_ejhf3560-bib-0031","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in acute myocardial infarction: The EMMY trial","volume":"43","author":"von Lewinski","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913023060700_ejhf3560-bib-0032","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.jacc.2024.03.405","article-title":"Left ventricular function, congestion, and effect of empagliflozin on heart failure risk after myocardial infarction","volume":"83","author":"Udell","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0033","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0735-1097(03)01057-X","article-title":"Predictors of late development of heart failure in stable survivors of myocardial infarction: The CARE study","volume":"42","author":"Lewis","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0034","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/eurheartj\/ehn062","article-title":"Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and\/or left ventricular dysfunction: A VALIANT study","volume":"29","author":"Lewis","year":"2008","journal-title":"Eur Heart J"},{"key":"2026010913023060700_ejhf3560-bib-0035","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0036","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913023060700_ejhf3560-bib-0037","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913023060700_ejhf3560-bib-0038","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jchf.2024.04.025","article-title":"Where are we with treatment and prevention of heart failure in patients post-myocardial infarction?","volume":"12","author":"Carberry","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026010913023060700_ejhf3560-bib-0039","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002834","article-title":"Temporal evolution of myocardial hemorrhage and edema in patients after acute ST-segment elevation myocardial infarction: Pathophysiological insights and clinical implications","volume":"5","author":"Carrick","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026010913023060700_ejhf3560-bib-0040","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.jacc.2024.03.408","article-title":"Clinical outcomes associated with various microvascular injury patterns identified by CMR after STEMI","volume":"83","author":"Lechner","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245684","article-title":"Association of myocardial hemorrhage and persistent microvascular obstruction with circulating inflammatory biomarkers in STEMI patients","volume":"16","author":"Bochaton","year":"2021","journal-title":"PLoS One"},{"key":"2026010913023060700_ejhf3560-bib-0042","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/S0735-1097(24)04349-3","article-title":"Myocardial tissue characterization after acute myocardial infarction with cardiac ultrasound radiomics (abstr)","volume":"83","author":"Jamthikar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026010913023060700_ejhf3560-bib-0043","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jchf.2019.08.014","article-title":"Left ventricular post-infarct remodeling: Implications for systolic function improvement and outcomes in the modern era","volume":"8","author":"van der Bijl","year":"2020","journal-title":"JACC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/3\/566\/65245698\/eurjhf_27_3_566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/27\/3\/566\/65245698\/eurjhf_27_3_566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:02:53Z","timestamp":1767981773000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/27\/3\/566\/8316362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,15]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3560","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,12,15]]},"assertion":[{"value":"2024-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}